Bionano Genomics, Inc. — Director's Dealing 2018

Oct 3, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BioNano Genomics, Inc (BNGO)
CIK: 0001411690
Period of Report: 2018-08-21

Reporting Person: BARKER DAVID L (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-08-21	Common Stock	P	3894	$6.47	Acquired	3894	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-08-21	Common Stock Warrants (right to buy)	$6.47	P	3894	Acquired	2023-08-21	Common Stock (3894)	Direct
2018-10-01	Stock Option (Right to Buy)	$7.77	A	10516	Acquired	2028-09-30	Common Stock (10516)	Direct

Footnotes

F1: The price reported in column 4 is a weighted average price. These units, with each unit consisting of one share of common stock and a warrant to purchase one share of common stock, were purchased in multiple transactions at prices ranging from $6.37 to $6.4971, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of units purchased at each separate price within the ranges set forth herein.
Units purchased at a price of $6.47 per unit, .

F2: September 21, 2018 or such earlier date as Roth Capital Partners LLC, as representative of the underwriters in the Company's Initial Public Offering, shall determine.

F3: The shares subject to the option shall vest monthly over 36 months beginning on the one-month anniversary of October 1, 2018 (the "Vesting Commencement Date") such that the option shall be fully vested and exercisable on the three year anniversary of the Vesting Commencement Date.